Erik C. B. Johnson

Proteomic Subtyping of Alzheimer's Disease CSF links Blood-Brain Barrier Dysfunction to Reduced levels of Tau and Synaptic Biomarkers

The paper identifies six CSF proteomic subtypes in Alzheimer's disease, linking BBB dysfunction to reduced tau and synaptic biomarkers, particularly in African Americans and men.

Aβ Amyloid Scaffolds the Accumulation of Matrisome and Additional Proteins in Alzheimer's Disease

The paper identifies a conserved Aβ amyloid 'responsome' in human and mouse AD brains, showing how amyloid scaffolds proteins involved in disease pathology.

Global analysis of the heparin-enriched plasma proteome captures matrisome-associated proteins in Alzheimer's disease

The paper uses heparin affinity chromatography to enrich plasma proteomes in Alzheimer's disease, identifying matrisome-associated proteins correlated with AD biomarkers.

Genetic background influences the 5XFAD Alzheimer's disease mouse model brain proteome

This study shows genetic background affects the proteome in 5XFAD AD mouse models, with some disease-related modules influenced by genetic background while others are not.

Quantitative proteomics of cerebrospinal fluid from African Americans and Caucasians reveals shared and divergent changes in Alzheimer's disease

The paper compares proteomic profiles of cerebrospinal fluid from African Americans and Caucasians with and without Alzheimer's disease to identify shared and divergent biomarkers.

Multi-Platform Proteomic Analysis of Alzheimer's Disease Cerebrospinal Fluid and Plasma Reveals Network Biomarkers Associated with Proteostasis and the Matrisome

The paper uses multi-platform proteomic analysis of CSF and plasma from Alzheimer's patients to identify biomarkers related to proteostasis and the matrisome.

Unbiased Classification of the Human Brain Proteome Resolves Distinct Clinical and Pathophysiological Subtypes of Cognitive Impairment

The paper uses proteomic profiling to classify cognitive impairment subtypes in human brain tissues, identifying distinct molecular patterns associated with different clinical outcomes.

Large-Scale Deep Multi-Layer Analysis of Alzheimer's Disease Brain Reveals Strong Proteomic Disease-Related Changes Not Observed at the RNA Level

The paper analyzes proteomic data from Alzheimer's disease brains, revealing disease-related changes not seen at the RNA level and identifying potential therapeutic targets.

Integrated Proteomics Reveals Brain-Based Cerebrospinal Fluid Biomarkers in Asymptomatic and Symptomatic Alzheimer’s Disease

The paper identifies brain-linked CSF biomarkers in Alzheimer’s disease using proteomics, revealing altered levels in both brain and CSF across different disease stages.

Identification of conserved proteomic networks in neurodegenerative dementia

The paper identifies conserved proteomic changes in neurodegenerative dementias, distinguishing AD and PSP genetic risk modules and showing some variance in protein expression is post-transcriptional.

A Consensus Proteomic Analysis of Alzheimer's Disease Brain and Cerebrospinal Fluid Reveals Early Changes in Energy Metabolism Associated with Microglia and Astrocyte Activation

The paper identifies protein network modules in Alzheimer's disease brains and cerebrospinal fluid that are associated with energy metabolism and neuroinflammation, suggesting potential biomarkers and therapeutic targets.